Clinical trials: Respiratory Virus Infection
Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus (RSV)
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
Phase 1 clinical trial to evaluate the safety of RSV-1 and RSV-2 vaccines in healthy adults aged 19 to 80 years who have voluntarily given written consent to participate in this study.
- Trial name
- EuRSV (NCT06216093)
- Testing
- EuRSV
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Influenza
Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old
Evaluate safety and immunogenicity of three influenza vaccines in children ages greater than 4 years old to less than 18 years old.
- Trial name
- NCT01992107
- Testing
- QIVc, TIV1c, TIV2c
- Where
- 88 sites in United States
- Volunteers
- 2,333 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Syncytial Viruses, Respiratory Tract Diseases
A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
The purpose of this study is to demonstrate the efficacy of active study vaccine in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed respiratory syncytial virus (RSV)-mediated lower respiratory…
- Trial name
- CYPRESS (NCT03982199)
- Testing
- RSV Vaccine
- Where
- 40 sites in United States
- Volunteers
- 5,815 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19
Sequential Immunization of Two Doses of Inactivated COVID-19 Vaccine (Omicron) in Vaccinated Population Aged 18 Years and Above
This trial adopts a randomized, double-blind and positive control design, it is planned to recruit 1800 healthy participants who have been vaccinated with 2/3 doses of COVID-19 inactivated vaccine or mRNA vaccine for 3 months.
- Trial name
- COVID-19 (NCT05382871)
- Testing
- BIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), WIBP Omicron Inactivated COVID-19 vaccine (Vero Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- Hong Kong
- Volunteers
- 1,804 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Influenza (Healthy Volunteers)
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older
Primary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants.
- Trial name
- NCT04537234
- Testing
- High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine
- Where
- 4 sites in Taiwan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine…
- Trial name
- COVID-19 (NCT05096832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01), Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)
- Where
- 18 sites in Malaysia, Pakistan
- Volunteers
- 10,381 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Influenza
Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults
The aim of the study is to evaluate the safety and immunogenicity of the 2015-2016 formulations of Fluzone Quadrivalent and Fluzone Intradermal Quadrivalent vaccines in adults 18 to < 65 years of age, and of the 2015-2016…
- Trial name
- NCT02563093
- Testing
- Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
- Where
- 4 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Avian Influenza
Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults
The main objective of the study is to assess the immune response to a non-adjuvanted H5N1 influenza vaccine in an adult population when administered according to a single prime-boost schedule.
- Trial name
- NCT00895544
- Testing
- Influenza vaccine (whole virion, Vero cell derived)
- Where
- 3 sites in Austria, Finland
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
SARS-CoV-2 Infection
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.
This is a randomized, double-blind, placebo-controlled study of RP7214 in patients with symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., age > 60 years, hypertension, diabetes mellitus, chronic…
- Trial name
- NCT05007236
- Testing
- RP7214 + Standard of care (SOC)
- Where
- 16 sites in India
- Volunteers
- 163 people
- Sponsor
- Rhizen Pharmaceuticals SA
Influenza Infection
Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults
This study will evaluate the safety and immunogenicity of VAX102 [Flagellin.HuM2e], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.
- Trial name
- NCT00603811
- Testing
- VAX102 [Flagellin.HuM2e]
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Respiratory Syncytial Virus (RSV)
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell)…
- Trial name
- NCT07272434
- Testing
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
- Where
- 8 sites in China
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Influenza, Human, Respiratory Tract Infections
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in…
- Conditions
- Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis
- Trial name
- Pearlstone (NCT07827599)
- Testing
- Baloxavir marboxil
- Where
- 8 sites in China
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
COVID 19
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 in Healthy Adult Subjects
- Trial name
- NCT04583228
- Testing
- HLX71
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hengenix Biotech Inc
Healthy
Assessing Choice in the Employer Setting (ACES) Study
The purpose of this study is to determine, among adults and in the total population, the effects of offering a choice of FluMist or trivalent inactivated vaccine (TIV) in the employer setting when compared to a control group.
- Trial name
- MA181 (NCT00808808)
- Testing
- Choice of TIV or FluMist with baseline advertisement, Choice of TIV or FluMist with enhanced advertisement and incentives, Control - Usual care offering TIV only with baseline advertisement
- Where
- 47 sites in United States
- Volunteers
- 4,411 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination
Immunogenicity and safety of a cell-derived influenza vaccine in adults aged >= 18 and <= 64 years, plus revaccination
- Trial name
- NCT00889889
- Testing
- Cell-Derived Trivalent Subunit Influenza Vaccine
- Where
- 15 sites in United States
- Volunteers
- 1,270 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
COVID-19
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated…
- Trial name
- NCT05765578
- Testing
- Moderna COVID-19 Vaccine, Moderna mRNA1273.222 Booster, Pfizer COVID-19 Vaccine
- Where
- United States
- Volunteers
- 1,713 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Novel 2009 Influenza H1N1, Influenza, Human
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
This is a single-blind, reference drug controlled study to assess safety and tolerability of FLUVAL P H1N1 monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL…
- Trial name
- NCT01407978
- Testing
- Vaccination with Fluval P monovalent influenza vaccine, Vaccination with Fluval AB, Vaccination with Fluval AB Novo
- Where
- Hungary
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children
The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.
- Trial name
- NCT01003418
- Testing
- GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine, Infanrix™-IPV/Hib, Prevenar
- Where
- 4 sites in Norway
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection
The purpose of this study is to evaluate the rate of decline in quantitative viral load measured in hospitalized patients with Influenza A infection
- Trial name
- NCT01992276
- Testing
- CR8020, CR6261
- Where
- 68 sites in United States, Australia and 10 more
- Sponsor
- Crucell Holland BV
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.